173 related articles for article (PubMed ID: 35841068)
1. The effect of nicotine-containing products and fetal sex on placenta-associated circulating midpregnancy biomarkers.
Sundet BK; Kreyberg I; Staff AC; Carlsen KCL; Bains KES; Berg JP; Granum B; Haugen G; Hedlin G; Jonassen CM; Nordhagen LS; Nordlund B; Rehbinder EM; Rudi K; Rueegg CS; Sjøborg KD; Skjerven HO; Söderhäll C; Vettukattil R; Sugulle M
Biol Sex Differ; 2022 Jul; 13(1):39. PubMed ID: 35841068
[TBL] [Abstract][Full Text] [Related]
2. Markers of placental function correlate with prevalence and quantity of nucleated fetal cells in maternal circulation in normotensive term pregnancies.
Fjeldstad HE; Jacobsen DP; Johnsen GM; Sugulle M; Chae A; Kanaan SB; Gammill HS; Staff AC
Acta Obstet Gynecol Scand; 2023 Jun; 102(6):690-698. PubMed ID: 36933003
[TBL] [Abstract][Full Text] [Related]
3. Early pregnancy maternal and fetal angiogenic factors and fetal and childhood growth: the Generation R Study.
Bergen NE; Bouwland-Both MI; Steegers-Theunissen RP; Hofman A; Russcher H; Lindemans J; Jaddoe VW; Steegers EA
Hum Reprod; 2015 Jun; 30(6):1302-13. PubMed ID: 25854264
[TBL] [Abstract][Full Text] [Related]
4. Novel circulating placental markers prokineticin-1, soluble fms-like tyrosine kinase-1, soluble endoglin and placental growth factor and association with late miscarriage.
Jayasena CN; Abbara A; Comninos AN; Narayanaswamy S; Gonzalez Maffe J; Izzi-Engbeaya C; Oldham J; Lee TT; Sarang Z; Malik Z; Dhanjal MK; Williamson C; Regan L; Bloom SR; Dhillo WS
Hum Reprod; 2016 Dec; 31(12):2681-2688. PubMed ID: 27664209
[TBL] [Abstract][Full Text] [Related]
5. The association between placenta-associated circulating biomarkers and composite adverse delivery outcome of a likely placental cause in healthy post-date pregnancies.
Bowe S; Mitlid-Mork B; Georgieva A; Gran JM; Redman CWG; Staff AC; Sugulle M
Acta Obstet Gynecol Scand; 2021 Oct; 100(10):1893-1901. PubMed ID: 34212381
[TBL] [Abstract][Full Text] [Related]
6. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
[TBL] [Abstract][Full Text] [Related]
7. Soluble fms-like tyrosine kinase to placental growth factor ratio in different stages of early-onset fetal growth restriction and small for gestational age.
Garcia-Manau P; Mendoza M; Bonacina E; Garrido-Gimenez C; Fernandez-Oliva A; Zanini J; Catalan M; Tur H; Serrano B; Carreras E
Acta Obstet Gynecol Scand; 2021 Jan; 100(1):119-128. PubMed ID: 32860218
[TBL] [Abstract][Full Text] [Related]
8. Urinary placental growth factor in preeclampsia and fetal growth restriction: An alternative to circulating biomarkers?
Zhang K; Zen M; Popovic NL; Lee VW; Alahakoon TI
J Obstet Gynaecol Res; 2019 Sep; 45(9):1828-1836. PubMed ID: 31257726
[TBL] [Abstract][Full Text] [Related]
9. Maternal placental growth factor and soluble fms-like tyrosine kinase-1 reference ranges in post-term pregnancies: A prospective observational study.
Mitlid-Mork B; Bowe S; Gran JM; Bolstad N; Berg JP; Redman CW; Staff AC; Sugulle M
PLoS One; 2020; 15(10):e0240473. PubMed ID: 33079955
[TBL] [Abstract][Full Text] [Related]
10. Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks' pregnancy in normotensive women.
Wataganara T; Pratumvinit B; Lahfahroengron P; Pooliam J; Talungchit P; Leetheeragul J; Sukpanichnant S
J Perinat Med; 2017 Oct; 45(7):895-901. PubMed ID: 28665791
[TBL] [Abstract][Full Text] [Related]
11. Can placental growth factors explain birthweight variation in offspring of women with type 1 diabetes?
Bacon S; Burger D; Tailor M; Sanchez JJ; Tomlinson G; Murphy HR; Feig DS;
Diabetologia; 2021 Jul; 64(7):1527-1537. PubMed ID: 33839801
[TBL] [Abstract][Full Text] [Related]
12. Correlation between placental weight and angiogenic markers sFlt-1 and PlGF in women with preeclampsia and fetal growth restriction.
Lorenz-Meyer LA; Frank L; Sroka D; Busjahn A; Henrich W; Verlohren S
Pregnancy Hypertens; 2022 Jun; 28():149-155. PubMed ID: 35453103
[TBL] [Abstract][Full Text] [Related]
13. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
[TBL] [Abstract][Full Text] [Related]
14. Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction.
Shinohara S; Uchida Y; Kasai M; Sunami R
Hypertens Pregnancy; 2017 Aug; 36(3):269-275. PubMed ID: 28737473
[TBL] [Abstract][Full Text] [Related]
15. Course of the sFlt-1/PlGF ratio in fetal growth restriction and correlation with biometric measurements, feto-maternal Doppler parameters and time to delivery.
Andrikos A; Andrikos D; Schmidt B; Birdir C; Kimmig R; Gellhaus A; Köninger A
Arch Gynecol Obstet; 2022 Mar; 305(3):597-605. PubMed ID: 34432111
[TBL] [Abstract][Full Text] [Related]
16. Omeprazole Administration in Preterm Preeclampsia: a Randomized Controlled Trial to Study Its Effect on sFlt-1 (Soluble Fms-Like Tyrosine Kinase-1), PlGF (Placental Growth Factor), and ET-1 (Endothelin-1).
Neuman RI; Baars MD; Saleh L; Broekhuizen M; Nieboer D; Cornette J; Schoenmakers S; Verhoeven M; Koch BCP; Russcher H; van den Berg SAA; van den Meiracker AH; Visser W; Danser AHJ
Hypertension; 2022 Jun; 79(6):1297-1307. PubMed ID: 35341328
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of impaired placentation at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
Ciobanou A; Jabak S; De Castro H; Frei L; Akolekar R; Nicolaides KH
Ultrasound Obstet Gynecol; 2019 Jul; 54(1):79-86. PubMed ID: 31100188
[TBL] [Abstract][Full Text] [Related]
18. The association between angiogenic markers and fetal sex: Implications for preeclampsia research.
Andersen LB; Jørgensen JS; Herse F; Andersen MS; Christesen HT; Dechend R
J Reprod Immunol; 2016 Sep; 117():24-9. PubMed ID: 27359072
[TBL] [Abstract][Full Text] [Related]
19. The predictive value of the sFlt-1/PlGF ratio on short-term absence of preeclampsia and maternal and fetal or neonatal complications in twin pregnancies.
Saleh L; Tahitu SIM; Danser AHJ; van den Meiracker AH; Visser W
Pregnancy Hypertens; 2018 Oct; 14():222-227. PubMed ID: 29678353
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Increased Maternal sFlt-1/PlGF Ratio on Motor Outcome of Preterm Infants.
Middendorf L; Gellhaus A; Iannaccone A; Köninger A; Dathe AK; Bendix I; Reisch B; Felderhoff-Mueser U; Huening B
Front Endocrinol (Lausanne); 2022; 13():913514. PubMed ID: 35846340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
